Allarity Therapeutics (Allarity Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Change In Inventory?

Allarity Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Allarity Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Allarity Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Allarity Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Allarity Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allarity Therapeutics Change In Inventory Historical Data

The historical data trend for Allarity Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Change In Inventory Chart

Allarity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Allarity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial											-	-	-	-	-

Allarity Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Allarity Therapeutics (NAS:ALLR) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Allarity Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Allarity Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allarity Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Allarity Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Allarity Therapeutics (Allarity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 School Street, 2nd Floor, Boston, MA, USA

Website

https://www.allarity.com

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Executives

Laura Benjamin	director	168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano	director	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown	officer: Chief Financial Officer	C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi	director, officer: Chief Executive Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen	officer: Chief Scientific Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen	officer: Chief Financial Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore	director	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen	officer: SVP, Information Technology	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem	officer: SVP, Chief Business Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh	officer: Chief Medical Officer	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps	10 percent owner	VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass	10 percent owner	JERNBAEK ALLE 5, HELSINGE G7 DK-3200